Inspire Medical Systems (NYSE:INSP) Trading Up 6.6% – What’s Next?

Inspire Medical Systems, Inc. (NYSE:INSP)’s stock price rose 6.6% during mid-day trading on Monday . The stock traded as high as $42.32 and last traded at $42.6960. Approximately 63,037 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 1,229,793 shares. The stock had previously closed at $40.05.

Analysts Set New Price Targets

Several research firms recently weighed in on INSP. Mizuho dropped their price target on Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. Truist Financial lowered their price objective on Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating for the company in a research report on Tuesday, May 5th. Stifel Nicolaus dropped their target price on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Bank of America reaffirmed a “neutral” rating and issued a $53.00 target price on shares of Inspire Medical Systems in a research report on Tuesday, May 5th. Finally, Robert W. Baird decreased their price target on shares of Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating for the company in a research note on Tuesday, May 5th. Four investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Inspire Medical Systems presently has an average rating of “Hold” and an average target price of $85.00.

Inspire Medical Systems Stock Performance

The stock has a 50-day simple moving average of $52.58 and a two-hundred day simple moving average of $76.92. The firm has a market cap of $1.23 billion, a PE ratio of 9.49, a price-to-earnings-growth ratio of 4.32 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The firm had revenue of $204.58 million for the quarter, compared to the consensus estimate of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, sell-side analysts anticipate that Inspire Medical Systems, Inc. will post 0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP purchased a new stake in Inspire Medical Systems in the 4th quarter worth $203,929,000. M&T Bank Corp bought a new position in shares of Inspire Medical Systems in the fourth quarter worth about $85,871,000. Deerfield Management Company L.P. boosted its stake in shares of Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after acquiring an additional 907,694 shares during the period. Morgan Stanley grew its position in shares of Inspire Medical Systems by 179.5% during the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after purchasing an additional 809,121 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. bought a new stake in Inspire Medical Systems during the 4th quarter valued at approximately $61,619,000. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.